MVManuelle Viguier

Manuelle Viguier

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuelle Viguier has a total of 434 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?

    by Wolf-Henning Boehncke, Maria-Magdalena Constantin, José-Manuel Carrascosa-Carrillo, Pariyawan Rakvit, Alice-Anaïs Varlet, Solenn Le Clanche, Linda A.W. Verhagen, Manuelle Viguier

    Methotrexate (MTX) is a widely used, cost-effective systemic treatment for moderate-to-severe psoriasis, but concerns about hepatotoxicity often limit its long-term use. Hepatic adverse effects range from transient enzyme elevations to fibrosis and cirrhosis. Despite established guidelines, monitoring practices remain inconsistent, and the mechanisms underlying MTX-induced hepatotoxicity in psoriasis patients are not fully elucidated. This systematic literature review evaluates the association between MTX and hepatotoxicity, identifies key risk factors, assesses monitoring strategies and addresses misconceptions about its hepatic safety. A comprehensive search of MEDLINE/PubMed, EMBASE, Cochrane Library and grey literature (2003–2024) included English and French studies on human subjects, encompassing guidelines, reviews and observational/interventional studies. MTX-related hepatotoxicity is multifactorial, with risk factors including obesity, diabetes, hyperlipidaemia, excessive alcohol consumption and pre-existing liver disease. Psoriasis itself may also contribute to liver dysfunction. There is no consensus on optimal monitoring frequency for liver function tests or the role of noninvasive tools like transient elastography. While folic acid supplementation may mitigate risk, dosing remains inconsistent.Though MTX carries a potential hepatotoxic risk, this is patient-specific rather than inherent to the drug. Standardized monitoring protocols and risk stratification are essential to optimize safety, prevent unnecessary treatment discontinuation and improve long-term psoriasis management.

  • Open Access

    French national protocol for diagnosis and management of pemphigoid gestationis

    by T. Bettuzzi, M. Bruet, F. Jouen, M. Alexandre, C.LE Roux-Villet, F. Caux, C. Lepelletier, E. Tancrède-Bohin, C. Picard-Dahan, F. Lombart, et al.

  • Open Access

    Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality

    by Manuelle Viguier, Denis Jullien, Laurent Misery, Christian Kromer, Maja Mockenhaupt, Bhargav Lakshminarasimhan, Marie Najean, Nichiren Pillai, Shah Alam Khan, Alice B. Gottlieb

    Introduction Generalized pustular psoriasis (GPP) is rare, chronic, and associated with life-threatening complications. We investigated the burden of GPP in France. Methods Using data from 2010 to 2021 in the Système National des Données de Santé database, healthcare resource utilization (HCRU), costs, comorbidities, mortality, and treatments were compared among GPP (N = 4351), plaque psoriasis (N = 12,945), and general population (N = 12,981) cohorts, matched for sex, age, Charlson Comorbidity Index (CCI) score, and region. GPP prevalence and incidence were also investigated. Results Annually, there were 0.5–0.8 new GPP cases per 100,000 people. Across the cohorts, 54.5–54.7% of people were male, with mean age 58.7–59.5 years and mean CCI score 1.98–2.06. The GPP cohort incurred significantly greater HCRU and costs versus the plaque psoriasis and general population cohorts, including greater proportions of patients receiving emergency care (78% vs 63% and 55%) and intensive care (28% vs 17% and 14%), longer hospitalizations (mean 38.5 vs 26.2 and 22.4 days per patient), and higher medication costs (€4360 vs €1991 and €1543 per patient-year), respectively. Despite similar CCI scores, GPP was associated with more cardiometabolic and psychological comorbidities versus the plaque psoriasis and general population cohorts, e.g., hypertension (37% vs 21% and 20%), obesity (21% vs 9% and 6%), depression (13% vs 4% and 4%), alcohol abuse (16% vs 3% and 3%), and sleep disorders (8% vs 4% and 3%), respectively. Treatments in the GPP cohort were those used for plaque psoriasis, including topical steroids (77%), systemic steroids (50%), and biologics (23%). Twelve-month survival was 86.9% (GPP), 97.5% (plaque psoriasis), and 90.0% (the general population). Conclusion HCRU, costs, and comorbidities with GPP were often double those for comparator cohorts, and mortality was higher. These findings highlight the need to use GPP-targeted treatments that improve patient outcomes and may reduce the burden on healthcare systems.


  • Prevalence of sleep disorders in patients with bullous pemphigoid

    by M. Alqahtani, M. Viguier, G. Chaby, G. Jeudy, C. Bedane, M. Alexandre, C. Picard-Dahan, S. Duvert Lehembre, C. Abasq, G. Quéreux, et al.

  • Ustekinumab as a potential therapeutic agent in bullous pemphigoid: a biologic and clinical proof-of-concept study

    by Vlada Koliadenko, Pascal Joly, Flora Lemaire, Saskia Ingen-Housz-Oro, Christophe Bedane, Frédéric Caux, Andrea Lopes, Delphine Giusti, Céline Muller, Billal Tedbirt, et al.

    We report promising clinical outcomes using ustekinumab as a first-line therapy in bullous pemphigoid when combined with a short, 8-week regimen of superpotent topical corticosteroids. Furthermore, the CD40 ligand/interleukin-4 ratio emerged as a potential predictive biomarker of treatment response, possibly reflecting a T helper 1-skewed immune environment that favours ustekinumab’s mechanism of action.


  • Erythrosis pigmentosa mediofacialis (Brocq): A hypothesis on the involvement of Demodex folliculorum

    by M. Piroth, A. Lopes, M. Vourc’h, E. Guigne, J.-M. Chavigny, S. Lachaise, C. Lenormand, B. Cribier, S. Barbarot, M. Viguier

  • Mammary and extramammary diffuse dermal angiomatosis: a case series and review of the literature

    by C. Decaestecker, E. Diaz, E. Crickx, J.-D. Bouaziz, C. Vanhaecke, M.-A. Viguier, E. Brenaut, D. Kottler, P. Courville, C. Tamarit, et al.


  • Open Access

    Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA

    by Caroline Robert, Emilie Gerard, Emilie Lanoy, Gaëlle Quéreux, P. Bernard, Manuelle-Anne Viguier, Florent Grange, N. Meyer, M. Dinulescu, Delphine Legoupil, et al.

    Background Cemiplimab an anti-programmed cell death receptor-1 antibody, was approved by the FDA and EMA for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) ineligible for curative surgery/radiotherapy or with metastatic (m) CSCC. TOSCA study evaluated the real-world effectiveness and safety of cemiplimab compared to historical systemic therapies (HSTs). Methods TOSCA (NCT05302297) was a large French retrospective, multicenter study comparing patient with la/mCSCC treated with cemiplimab via the early access program (EAP, 2018–2019) or HST (2013–2018). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall response rate (ORR), and safety. Effectiveness analysis using inverse probability weighting included a trial-like cohort of only immunocompetent patients meeting the EAP criteria to emulate a randomized clinical trial; safety analysis included all real-life patients. Findings The study included 280 real-life patients (cemiplimab: n=147; HST: n=133). The primary effectiveness analysis included a trial-like cohort (cemiplimab: n=129; HST: n=70; median age: 81 and 78 years, respectively). Median follow-up was 20 and 10 months in the cemiplimab and HST arms, respectively; median OS was 21.2 and 9.8 months, respectively (HR 95% CI: 0.57 [0.45–0.73]; P<0.0001); median PFS was 13.7 and 5.3 months, respectively (HR [95% CI]: 0.57 [0.43–0.76]; P=0.0001). Adverse drug reactions occurred in 27% of cemiplimab patients and 33% of HST patients. . Interpretation TOSCA demonstrated better survival and response outcomes for cemiplimab versus HST in la/mCSCC; emphasizing, the importance of rigorous retrospective studies in the absence of standard comparative trials. Funding Sanofi.

  • Open Access

    Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients

    by Kevin Didier, Vincent Sobanski, Ailsa Robbins, Marie-Elise Truchetet, Thomas Barnetche, Cécile Contin-Bordes, Arnaud Hot, Romain Fort, Philippe Guilpain, Alexandre Maria, et al.

    Introduction Systemic sclerosis (SSc) is a rare autoimmune disease currently classified into two subgroups based on skin extension. The aim of this study was to determine in a large cohort whether the determination of autoantibody (AAb) profile among a full antinuclear AAbs panel including nine specificities had a higher impact than skin phenotype on stratifying the risk of organ involvement and mortality in SSc. Methods Data for patients with SSc followed in seven French university hospitals were retrospectively analysed in terms of skin phenotype, AAbs (anti-topoisomerase I (ATA), anticentromere (ACA), anti-RNA polymerase III (anti-RNAPIII), anti-U1RNP, anti-U3RNP, anti-Pm/Scl, anti-Ku, anti-Th/To, anti-NOR90), organ involvement and mortality. Multivariate analyses were performed to identify independent factors associated with organ involvement and mortality. Results We included 1605 patients with SSc (367 with diffuse cutaneous SSc). On multivariate analysis, ATAs were associated with interstitial lung disease and mortality (OR=3.27 (95% CI 2.42 to 4.42); HR=1.9 (95% CI 1.01 to 3.58)), anti-RNAPIII with scleroderma renal crisis and mortality (OR=7.05 (95% CI 2.98 to 16.72); HR=2.35 (95% CI 1.12 to 4.93)), anti-U1RNP with arthritis (OR=3.79 (95% CI 2.16 to 6.67)), anti-Pm/Scl and anti-Ku with myositis (OR=7.09 (95% CI 3.87 to 12.98) and 7.99 (95% CI 2.41 to 26.46)). The skin phenotype was not associated with survival or organ involvement on multivariate analysis without stepwise selection. Conclusion This study unravels, by contrast with skin phenotype, a strong association between AAbs specificities, organ involvement and outcome in SSc and suggests that patients’ classification based on only skin extension is not sufficient for defining prognosis and phenotype.